Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT

S. O. Ciurea, R. Saliba, G. Rondon, S. Pesoa, P. Cano, M. Fernandez-Vina, S. Qureshi, L. L. Worth, J. McMannis, P. Kebriaei, R. B. Jones, M. Korbling, M. Qazilbash, E. J. Shpall, S. Giralt, M. De Lima, R. E. Champlin, J. Gajewski

    Research output: Contribution to journalArticle

    44 Citations (Scopus)

    Abstract

    Haploidentical SCT (HaploSCT) has been most commonly performed using a myeloablative, TBI-based preparative regimen; however, the toxicity with this approach remains very high. We studied the feasibility of a reduced-intensity conditioning regimen in a phase II clinical trial using fludarabine, melphalan and thiotepa and antithymocyte globulin (ATG) for patients with advanced hematological malignancies undergoing T-cell depleted HaploSCT. Twenty-eight patients were entered in the study. Engraftment with donor-derived hematopoiesis was achieved in 78 of patients after a median of 13 days. Six patients experienced primary graft failure, three out of four tested patients had donor-specific anti-HLA antibodies (DSA) (P0.001). Toxicity included mostly infections. A total of 21 out of 22 patients with AMLmyelodysplastic syndrome (MDS) achieved remission after transplant (16 with relapsedrefractory AML). Five out of the 12 patients (42) with AMLMDS with

    Original languageEnglish (US)
    Pages (from-to)429-436
    Number of pages8
    JournalBone Marrow Transplantation
    Volume45
    Issue number3
    DOIs
    StatePublished - 2010

    Fingerprint

    Thiotepa
    Melphalan
    Tissue Donors
    Transplants
    Phase II Clinical Trials
    Antilymphocyte Serum
    Hematopoiesis
    Hematologic Neoplasms
    fludarabine
    Anti-Idiotypic Antibodies
    T-Lymphocytes
    Infection

    Keywords

    • AML
    • Haploidentical SCT
    • Myelodysplastic syndromes
    • T-cell depletion

    ASJC Scopus subject areas

    • Hematology
    • Transplantation

    Cite this

    Ciurea, S. O., Saliba, R., Rondon, G., Pesoa, S., Cano, P., Fernandez-Vina, M., ... Gajewski, J. (2010). Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplantation, 45(3), 429-436. https://doi.org/10.1038/bmt.2009.189

    Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. / Ciurea, S. O.; Saliba, R.; Rondon, G.; Pesoa, S.; Cano, P.; Fernandez-Vina, M.; Qureshi, S.; Worth, L. L.; McMannis, J.; Kebriaei, P.; Jones, R. B.; Korbling, M.; Qazilbash, M.; Shpall, E. J.; Giralt, S.; Lima, M. De; Champlin, R. E.; Gajewski, J.

    In: Bone Marrow Transplantation, Vol. 45, No. 3, 2010, p. 429-436.

    Research output: Contribution to journalArticle

    Ciurea, SO, Saliba, R, Rondon, G, Pesoa, S, Cano, P, Fernandez-Vina, M, Qureshi, S, Worth, LL, McMannis, J, Kebriaei, P, Jones, RB, Korbling, M, Qazilbash, M, Shpall, EJ, Giralt, S, Lima, MD, Champlin, RE & Gajewski, J 2010, 'Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT', Bone Marrow Transplantation, vol. 45, no. 3, pp. 429-436. https://doi.org/10.1038/bmt.2009.189
    Ciurea, S. O. ; Saliba, R. ; Rondon, G. ; Pesoa, S. ; Cano, P. ; Fernandez-Vina, M. ; Qureshi, S. ; Worth, L. L. ; McMannis, J. ; Kebriaei, P. ; Jones, R. B. ; Korbling, M. ; Qazilbash, M. ; Shpall, E. J. ; Giralt, S. ; Lima, M. De ; Champlin, R. E. ; Gajewski, J. / Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. In: Bone Marrow Transplantation. 2010 ; Vol. 45, No. 3. pp. 429-436.
    @article{0db74311d07f405580d9fcd83a9ee08d,
    title = "Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT",
    abstract = "Haploidentical SCT (HaploSCT) has been most commonly performed using a myeloablative, TBI-based preparative regimen; however, the toxicity with this approach remains very high. We studied the feasibility of a reduced-intensity conditioning regimen in a phase II clinical trial using fludarabine, melphalan and thiotepa and antithymocyte globulin (ATG) for patients with advanced hematological malignancies undergoing T-cell depleted HaploSCT. Twenty-eight patients were entered in the study. Engraftment with donor-derived hematopoiesis was achieved in 78 of patients after a median of 13 days. Six patients experienced primary graft failure, three out of four tested patients had donor-specific anti-HLA antibodies (DSA) (P0.001). Toxicity included mostly infections. A total of 21 out of 22 patients with AMLmyelodysplastic syndrome (MDS) achieved remission after transplant (16 with relapsedrefractory AML). Five out of the 12 patients (42) with AMLMDS with",
    keywords = "AML, Haploidentical SCT, Myelodysplastic syndromes, T-cell depletion",
    author = "Ciurea, {S. O.} and R. Saliba and G. Rondon and S. Pesoa and P. Cano and M. Fernandez-Vina and S. Qureshi and Worth, {L. L.} and J. McMannis and P. Kebriaei and Jones, {R. B.} and M. Korbling and M. Qazilbash and Shpall, {E. J.} and S. Giralt and Lima, {M. De} and Champlin, {R. E.} and J. Gajewski",
    year = "2010",
    doi = "10.1038/bmt.2009.189",
    language = "English (US)",
    volume = "45",
    pages = "429--436",
    journal = "Bone Marrow Transplantation",
    issn = "0268-3369",
    publisher = "Nature Publishing Group",
    number = "3",

    }

    TY - JOUR

    T1 - Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT

    AU - Ciurea, S. O.

    AU - Saliba, R.

    AU - Rondon, G.

    AU - Pesoa, S.

    AU - Cano, P.

    AU - Fernandez-Vina, M.

    AU - Qureshi, S.

    AU - Worth, L. L.

    AU - McMannis, J.

    AU - Kebriaei, P.

    AU - Jones, R. B.

    AU - Korbling, M.

    AU - Qazilbash, M.

    AU - Shpall, E. J.

    AU - Giralt, S.

    AU - Lima, M. De

    AU - Champlin, R. E.

    AU - Gajewski, J.

    PY - 2010

    Y1 - 2010

    N2 - Haploidentical SCT (HaploSCT) has been most commonly performed using a myeloablative, TBI-based preparative regimen; however, the toxicity with this approach remains very high. We studied the feasibility of a reduced-intensity conditioning regimen in a phase II clinical trial using fludarabine, melphalan and thiotepa and antithymocyte globulin (ATG) for patients with advanced hematological malignancies undergoing T-cell depleted HaploSCT. Twenty-eight patients were entered in the study. Engraftment with donor-derived hematopoiesis was achieved in 78 of patients after a median of 13 days. Six patients experienced primary graft failure, three out of four tested patients had donor-specific anti-HLA antibodies (DSA) (P0.001). Toxicity included mostly infections. A total of 21 out of 22 patients with AMLmyelodysplastic syndrome (MDS) achieved remission after transplant (16 with relapsedrefractory AML). Five out of the 12 patients (42) with AMLMDS with

    AB - Haploidentical SCT (HaploSCT) has been most commonly performed using a myeloablative, TBI-based preparative regimen; however, the toxicity with this approach remains very high. We studied the feasibility of a reduced-intensity conditioning regimen in a phase II clinical trial using fludarabine, melphalan and thiotepa and antithymocyte globulin (ATG) for patients with advanced hematological malignancies undergoing T-cell depleted HaploSCT. Twenty-eight patients were entered in the study. Engraftment with donor-derived hematopoiesis was achieved in 78 of patients after a median of 13 days. Six patients experienced primary graft failure, three out of four tested patients had donor-specific anti-HLA antibodies (DSA) (P0.001). Toxicity included mostly infections. A total of 21 out of 22 patients with AMLmyelodysplastic syndrome (MDS) achieved remission after transplant (16 with relapsedrefractory AML). Five out of the 12 patients (42) with AMLMDS with

    KW - AML

    KW - Haploidentical SCT

    KW - Myelodysplastic syndromes

    KW - T-cell depletion

    UR - http://www.scopus.com/inward/record.url?scp=77949423221&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=77949423221&partnerID=8YFLogxK

    U2 - 10.1038/bmt.2009.189

    DO - 10.1038/bmt.2009.189

    M3 - Article

    VL - 45

    SP - 429

    EP - 436

    JO - Bone Marrow Transplantation

    JF - Bone Marrow Transplantation

    SN - 0268-3369

    IS - 3

    ER -